Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing
Roots Analysis is pleased to announce the publication of its recent study, titled, “Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030.”
The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing
Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market
An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013
An analysis of the expansions related to continuous manufacturing, which have been established since 2013
An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).
A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019
An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019
Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
A review of the companies offering modular facilities / modular cleanrooms